Hai cercato la traduzione di urinary straining da Danese a Portoghese

- dogs - hormone dependent urinary incontinence
- hormone dependent urinary incontinence

treatment of carcinoma in situ of the urinary bladder
treatment of carcinoma in situ of the urinary bladder

dogs hormone - dependent urinary incontinence (qg03ca04)
dogs hormone - dependent urinary incontinence (qg03ca04)

eau guidelines for the management of urinary and male genital tract infections.
5 eau guidelines for the management of urinary and male genital tract infections.

comparison of three dosage regimens of ciprofloxacin in urinary tract infections.
comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of escherichia coli.
mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of escherichia coli.

note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women
note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women

single- dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:
single- dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:

concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women
concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women

once- daily fleroxacin versus twice- daily ciprofloxacin in the treatment of complicated urinary tract infectionsj urol 1997; 158:
once- daily fleroxacin versus twice- daily ciprofloxacin in the treatment of complicated urinary tract infectionsj urol 1997; 158:

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: